BioAlliance Pharma Announces the Launch of Oravig® in the United States by Its New Partner, Vestiq Pharmaceuticals

Published: Jan 07, 2013

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the launch of Oravig® (known as Loramyc® in Europe) in the United States by its commercial partner, Vestiq Pharmaceuticals.

Back to news